Eli Lilly sues Canadian government for “unfair” patent rulings
Eli Lilly has filed a NOA against the Canadian government, alleging recent decisions that invalidated patents covering its Zyprexa and Strattera drugs were in breach of NAFTA.
Foreign drug makers claim monopoly on Indian patents
The Indian government has awarded more than two thirds of its recent pharmaceutical patents to foreign drug makers, according to data released by the Indian Patent Office.
India recommends compulsory licence for anti-cancer drug
The Health Ministry in India has recommended that a compulsory licence is issued for the manufacture of Bristol-Myers Squibb’s anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.
PolyTherics completes Antitope takeover
UK biopharmaceuticals company PolyTherics has completed a takeover of Antitope, a provider of antibody engineering and immunogenicity screening services.
AIPPI 2013: Pharmaceutical products and the trademark hiccup
The annual International Association for the Protection of Intellectual Property conference in Helsinki has been assessing the potential problems for pharmaceutical companies trying to brand their medicinal products.
BioEconomy Academy launches in Bangkok
Law firm Rouse has teamed up with two organisations to open the BioEconomy Academy, an initiative aimed at boosting IP use and awareness in Thailand.
Amici submit brief to support Ambry in Myriad case
The American Civil Liberties Union and other groups have submitted an amici curiae brief in support of Ambry Genetics and Gene by Gene in their patent infringement cases with Myriad Genetics Inc.
Marks & Clerk UK promotes two to partnership
UK IP firm Marks & Clerk LLP has announced two of its attorneys will be joining the firm’s partnership.
Austria becomes first country to ratify Unified Patent Court agreement
Austria has become the first country in the EU to ratify consent to the Unified Patent Court.
Miles & Stockbridge welcomes eight IP professionals
US law firm Miles & Stockbridge PC has continued the expansion of its IP practice with the addition of seven lawyers and one patent agent.
